Neurotech Pharmaceuticals

Private

#Ophthalmology #Retinal Diseases #Cell Therapy

Biotechnology company that pioneered Encapsulated Cell Therapy (ECT) to provide continuous, long-term intraocular protein delivery for retinal diseases, developer of FDA-approved ENCELTO for MacTel.

Company Info

Sector:Cell Therapy / Ophthalmology

Headquarters:Cumberland, Rhode Island

Founded:2000

Website:www.neurotechusa.com/

Clinical Development Pipeline

ENCELTO (revakinagene taroretcel-lwey / NT-501)

Target: Ciliary Neurotrophic Factor (CNTF) Encapsulated Cell Therapy

Macular Telangiectasia Type 2 (MacTel)

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Richard Small

Chief Executive Officer

Careers & Job Openings

No active job listings. Check back later.